GlassScriptPhysician profile
Sonja K Olsen
NPI 1124221882
$220,410.85
in general payments reported to CMS, 2019-2025
26 companies · $150K in 2025
The $150K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $12.25 · 2022: $169 · 2023: $8,099 · 2024: $62K · 2025: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Travel and Lodging: $11K · Consulting Fee: $7,095 · Food and Beverage: $6,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,674.50 |
| Travel and Lodging | $11,245.85 |
| Consulting Fee | $7,095.00 |
| Food and Beverage | $6,970.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $193,270.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $24,857.87 | 2023-2025 | |
| Celgene Corporation | $330.41 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $217.68 | 2023-2025 | Stelara, Simponi, Remicade |
| Medtronic, INC. | $203.06 | 2023 | Interstim |
| Novo Nordisk INC | $162.40 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.56 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $140.33 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $139.26 | 2023-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $133.22 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $128.90 | 2022-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2023 | Zeposia |
| Dova Pharmaceuticals | $119.09 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.69 | 2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $68.48 | 2023-2024 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $67.65 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $33.73 | 2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $29.43 | 2025 | Terlivaz |
| Lilly USA, LLC | $24.37 | 2025 | Omvoh |
| Redhill Biopharma INC. | $24.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.38 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $17.19 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $16.72 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $14.33 | 2023 | Valve Kits |
| Pfizer INC. | $13.13 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonja Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.